Major Depressive Disorder: Eight-Market Drug Forecast and Market Analysis - Update (2025)
Summary
This report covers the 8 major markets and provides an Excel-based forecast model for the Major Depressive Disorder market through 2029.
GlobalData estimated that drug sales for MDD in 2019 were approximately $4.73 billion across the 8MM. The US market makes up the majority of total global sales, contributing $3.35 billion (70.7%) due to the large MDD prevalent population, combined with the high price of medication in the country. GlobalData anticipates that the MDD market will grow to be worth approximately $9.55 billion by 2029, at a compound annual growth rate (CAGR) of 7.3%. The US is expected to maintain its position as the market leader in 2029, increasing the proportion of global sales it accounts for to 84.7%
The major drivers of growth in the MDD market in the 8MM over the forecast period include:
The launch of six new pipeline products throughout the 8MM, which will have significantly higher costs of therapy when compared with the cost of the most commonly used MDD treatments that have high generic availability.
In the 8MM, the number of 12-month total prevalent cases of MDD is expected to increase during the forecast period.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook